^
    CANCER:

    Ovarian Serous Adenocarcinoma

    Related cancers:
    BRAF V600E
    Ovarian Serous Adenocarcinoma
    encorafenib + binimetinib
    Sensitive: C1 - Off-label
    BRCA2 mutation
    Ovarian Serous Adenocarcinoma
    olaparib
    Sensitive: C1 - Off-label
    BRCA1 mutation
    Ovarian Serous Adenocarcinoma
    olaparib
    Sensitive: C1 - Off-label
    BRCA1 mutation
    Ovarian Serous Adenocarcinoma
    olaparib + LY2606368
    Sensitive: C2 – Inclusion Criteria
    KRAS G12V
    Ovarian Serous Adenocarcinoma
    VS-6766 + VS-6063
    Sensitive: C2 – Inclusion Criteria
    KRAS G12D
    Ovarian Serous Adenocarcinoma
    VS-6766 + VS-6063
    Sensitive: C3 – Early Trials
    KRAS G12A
    Ovarian Serous Adenocarcinoma
    VS-6766 + VS-6063
    Sensitive: C3 – Early Trials
    Choline elevation
    Ovarian Serous Adenocarcinoma
    pembrolizumab
    Sensitive: C3 – Early Trials
    SERPINE1 expression
    Ovarian Serous Adenocarcinoma
    trametinib
    Sensitive: C3 – Early Trials
    BRCA1 mutation
    Ovarian Serous Adenocarcinoma
    AZD1775
    Sensitive: C4 – Case Studies
    GOPC-ROS1 fusion
    Ovarian Serous Adenocarcinoma
    crizotinib
    Sensitive: C4 – Case Studies
    ER Y537N
    Ovarian Serous Adenocarcinoma
    fulvestrant
    Sensitive: C4 – Case Studies
    TMB-H + MSH6 F1088fs
    Ovarian Serous Adenocarcinoma
    pembrolizumab
    Sensitive: C4 – Case Studies
    BRCA2 mutation
    Ovarian Serous Adenocarcinoma
    LY2606368 + LY3023414
    Sensitive: D – Preclinical
    BRAF L485-P490 deletion
    Ovarian Serous Adenocarcinoma
    LY3009120
    Sensitive: D – Preclinical
    PRMT1 underexpression
    Ovarian Serous Adenocarcinoma
    carboplatin
    Sensitive: D – Preclinical
    PRMT1 underexpression
    Ovarian Serous Adenocarcinoma
    cisplatin
    Sensitive: D – Preclinical